Based on the Neumora Therapeutics, Inc. stock forecast from 5 analysts, the average analyst target price for Neumora Therapeutics, Inc. is USD 18.46 over the next 12 months. Neumora Therapeutics, Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Neumora Therapeutics, Inc. is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Neumora Therapeutics, Inc.’s stock price was USD 1.43. Neumora Therapeutics, Inc.’s stock price has changed by +1.42% over the past week, -14.37% over the past month and -92.08% over the last year.
No recent analyst target price found for Neumora Therapeutics, Inc.
No recent average analyst rating found for Neumora Therapeutics, Inc.
Company Overview Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. Read Less
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid r...Read More
Frequently Asked Questions About Neumora Therapeutics, Inc. (NMRA) Stock
Based on ratings from 5 analysts Neumora Therapeutics, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on NMRA's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for NMRA is USD 18.46 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on NMRA's stock to indicate if its overvalued.
The last closing price of NMRA's stock was USD 1.43.
The most recent market capitalization for NMRA is USD 0.28B.
Based on targets from 5 analysts, the average taret price for NMRA is projected at USD 18.46 over the next 12 months.
This means that NMRA's stock price may go up by +1,191.02% over the next 12 months.
We can't find any ETFs which contains Neumora Therapeutics, Inc.'s stock.
As per our most recent records Neumora Therapeutics, Inc. has 109 Employees.
Neumora Therapeutics, Inc.'s registered address is 490 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Neumora Therapeutics, Inc.'s website at https://www.neumoratx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Neumora Therapeutics, Inc. (NMRA) Stock
Based on ratings from 5 analysts Neumora Therapeutics, Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on NMRA's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for NMRA is USD 18.46 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on NMRA's stock to indicate if its overvalued.
The last closing price of NMRA's stock was USD 1.43.
The most recent market capitalization for NMRA is USD 0.28B.
Based on targets from 5 analysts, the average taret price for NMRA is projected at USD 18.46 over the next 12 months.
This means that NMRA's stock price may go up by +1,191.02% over the next 12 months.
We can't find any ETFs which contains Neumora Therapeutics, Inc.'s stock.
As per our most recent records Neumora Therapeutics, Inc. has 109 Employees.
Neumora Therapeutics, Inc.'s registered address is 490 Arsenal Way, Watertown, MA, United States, 02472.
You can get more information about it from Neumora Therapeutics, Inc.'s website at https://www.neumoratx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NMRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
